PDF(Pubmed)
Abstract：
Background: Dupilumab is a monoclonal antibody used for the treatment of moderate/severe atopic dermatitis (AD). In recent years, several studies have confirmed the positive association between AD and overweight/obesity, and a report demonstrated the effect of weight reduction on the improvement of AD symptoms. Methods: The weight of 170 patients under treatment with dupilumab was recorded at baseline and after 48 weeks (T48). Clinical monitoring was mainly conducted using the Eczema Area and Severity Index (EASI). The study aimed to assess a possible correlation between the clinical outcome of dupilumab therapy and BMI. Results: Although not statistically significant, patients with a BMI < 25 have a higher EASI percentage improvement than patients with a BMI ≥ 25 at any time point, and the percentage of overweight and obese patients that does not reach EASI-75 at T48 is higher compared to normal-weight patients (13.5% vs. 5.9%). Despite this, in the multivariate regression analysis, no baseline characteristic, including BMI, appears to increase the risk of not reaching EASI-75. In addition, the results show no differences in BMI between baseline and T48 in any age/sex group. Conclusions: The results suggest that overweight and obese patients have a lower response to dupilumab when considering the EASI score, but this difference does not appear to be clinically significant. Furthermore, dupilumab treatment does not seem to impact weight.
摘要：
背景：Dupilumab是一种用于治疗中度/重度特应性皮炎（AD）的单克隆抗体。近年来,几项研究证实了AD与超重/肥胖之间的正相关，一份报告证明了减轻体重对改善AD症状的作用。方法：在基线和48周后（T48）记录170例接受dupilumab治疗的患者的体重。临床监测主要采用湿疹面积和严重程度指数(EASI)。该研究旨在评估dupilumab治疗的临床结果与BMI之间可能的相关性。结果：虽然没有统计学意义，BMI<25的患者在任何时间点都比BMI≥25的患者有更高的EASI改善百分比,与体重正常的患者相比，在T48时未达到EASI-75的超重和肥胖患者的百分比更高（13.5％vs.5.9%）。尽管如此,在多元回归分析中，无基线特征,包括BMI,似乎增加了未达到EASI-75的风险。此外,结果显示,在任何年龄/性别组,基线和T48之间的BMI没有差异.结论：研究结果表明，当考虑EASI评分时，超重和肥胖患者对dupilumab的反应较低，但这种差异在临床上似乎并不显著。此外，dupilumab治疗似乎不会影响体重.
